Objective Responses to First-Line Neoadjuvant Carboplatin-Paclitaxel Regimens for Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Objective Responses to First-Line Neoadjuvant Carboplatin-Paclitaxel Regimens for Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (ICON8): Post-Hoc Exploratory Analysis of a Randomised, Phase 3 Trial
Lancet Oncol 2020 Dec 22;[EPub Ahead of Print], RD Morgan, IA McNeish, AD Cook, EC James, R Lord, G Dark, RM Glasspool, J Krell, C Parkinson, CJ Poole, M Hall, D Gallardo-Rincón, M Lockley, S Essapen, J Summers, A Anand, A Zachariah, S Williams, R Jones, K Scatchard, A Walther, JW Kim, S Sundar, GC Jayson, JA Ledermann, AR ClampFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.